24444-74-4Relevant articles and documents
1-substituted (dibenzo[ b,d ]thiophen-4-yl)-2-morpholino-4 h -chromen-4-ones endowed with dual DNA-PK/PI3-K inhibitory activity
Cano, Céline,Saravanan, Kappusamy,Bailey, Chris,Bardos, Julia,Curtin, Nicola J.,Frigerio, Mark,Golding, Bernard T.,Hardcastle, Ian R.,Hummersone, Marc G.,Menear, Keith A.,Newell, David R.,Richardson, Caroline J.,Shea,Smith, Graeme C. M.,Thommes, Pia,Ting, Attilla,Griffin, Roger J.
, p. 6386 - 6401 (2013)
Analogues of (dibenzo[b,d]thiophen-4-yl)-2-morpholino-4H-chromen-4-one (NU7441), a potent inhibitor of DNA-dependent protein kinase (DNA-PK; IC 50 = 42 ± 2 nM), have been synthesized in which water-solubilizing groups [NHCO(CH2)nNR1R 2, where n = 1 or 2 and the moiety R1R2N was derived from a library of primary and secondary amines, e.g., morpholine] were placed at the 1-position. Several of the newly synthesized compounds exhibited high potency against DNA-PK and potentiated the cytotoxicity of ionizing radiation (IR) in vitro 10-fold or more (e.g., 2-(4-ethylpiperazin-1-yl)-N-(4- (2-morpholino-4-oxo-4H-chromen-8-yl)dibenzo[b,d]thio-phen-1-yl)acetamide, 39; DNA-PK IC50 = 5.0 ± 1 nM, IR dose modification ratio = 13). Furthermore, 39 was shown to potentiate not only IR in vitro but also DNA-inducing cytotoxic anticancer agents, both in vitro and in vivo. Counter-screening against other members of the phosphatidylinositol 3-kinase (PI-3K) related kinase (PIKK) family unexpectedly revealed that some of the compounds were potent mixed DNA-PK and PI-3K inhibitors.
INHIBITORS OF TRKA KINASE
-
, (2016/08/17)
The present invention is directed to the compounds of Formula I which are inhibitors of tropomyosin-related kinase A (TrkA): Formula (I) or steroisomers, tautomers or a pharmaceutically acceptable salts, metabolites, isotopes, solvates or prodrugs thereof
DNA-dependent protein kinase (DNA-PK) inhibitors. synthesis and biological activity of quinolin-4-one and pyridopyrimidin-4-one surrogates for the chromen-4-one chemotype
Cano, Céline,Barbeau, Olivier R.,Bailey, Christine,Cockcroft, Xiao-Ling,Curtin, Nicola J.,Duggan, Heather,Frigerio, Mark,Golding, Bernard T.,Hardcastle, Ian R.,Hummersone, Marc G.,Knights, Charlotte,Menear, Keith A.,Newell, David R.,Richardson, Caroline J.,Smith, Graeme C. M.,Spittle, Ben,Griffin, Roger J.
, p. 8498 - 8507 (2011/03/17)
Following the discovery of dibenzo[b,d]thiophen-4-yl)-2-morpholino-4H- chromen-4-one (NU7441) (Leahy, J. J. J.; Golding, B. T.; Griffin, R. J.; Hardcastle, I. R.; Richardson, C.; Rigoreau, L.; Smith, G. C. M. Bioorg. Med. Chem. Lett. 2004, 14, 6083-6087) as a potent inhibitor (IC50 = 30 nM) of DNA-dependent protein kinase (DNA-PK), we have investigated analogues in which the chromen-4-one core template has been replaced by aza-heterocyclic systems: 9-substituted 2-morpholin-4-ylpyrido[1,2-a]pyrimidin-4-ones and 8-substituted 2-morpholin-4-yl-1H-quinolin-4-ones. The 8- and 9-substituents were either dibenzothiophen-4-yl or dibenzofuran-4-yl, which were each further substituted at the 1-position with water-solubilizing groups [NHCO(CH 2)nNR1R2, where n = 1 or 2 and the moiety R1R2N was derived from a library of primary and secondary amines (e.g., morpholine)]. The inhibitors were synthesized by employing a multiple-parallel approach in which the two heterocyclic components were assembled by Suzuki-Miyaura cross-coupling. Potent DNA-PK inhibitory activity was generally observed across the compound series, with structure activity studies indicating that optimal potency resided in pyridopyrimidin-4- ones bearing a substituted dibenzothiophen-4-yl group. Several of the newly synthesized compounds (e.g., 2-morpholin-4-yl-N-[4-(2-morpholin-4-yl-4-oxo-4H- pyrido[1,2-a]pyrimidin-9-yl)dibenzothiophen-1-yl]acetamide) combined high potency against the target enzyme (DNA-PK IC50 = 8 nM) with promising activity as potentiators of ionizing radiation-induced cytotoxicity in vitro.
